Mats Rudling

Mats Rudling is a Professor of Experimental Cardiovascular Research at the Karolinska Institutet, jointly affiliated with the Department of Bioscience and Nutrition and the Department of Medicine, Huddinge. His research is centered on the regulation of cholesterol and bile acid metabolism, with implications for cardiovascular disease, diabetes, and liver disorders.

• Cardiology and Cardiovascular Disease
• Endocrinology and Diabetes
• Gastroenterology and Hepatology
• Cholesterol and Bile Acid Metabolism
• Hormonal Regulation of Lipid Homeostasis

His research investigates how hormones such as thyroid hormone, estrogen, and growth hormone modulate hepatic lipid metabolism, with a focus on key regulators like PCSK9, FGF19, and FXR. He employs both human clinical studies and murine models to explore metabolic pathways related to atherosclerosis, gallstone formation, fatty liver disease, and obesity. His work often bridges molecular mechanisms with clinical outcomes, contributing to the understanding of metabolic diseases and potential therapeutic interventions.

The 15 most recent articles highlight a consistent focus on bile acid physiology, cholesterol homeostasis, and hormonal regulation. The research spans clinical trials, animal models, and molecular mechanisms, with recurring themes in FXR signaling, PCSK9 modulation, and interstitial lipoprotein dynamics. There is a strong emphasis on translational metabolism, linking basic science to human disease.

• Active principal investigator with long-standing funding and collaborations
• Extensive publication record in high-impact journals
• Collaborates with leading experts in endocrinology and lipidology
• No formal advising roles or student supervision listed

Dr. Rudling’s work is conducted within the research environment of the Karolinska Institutet, a leading medical university in Sweden. He has been involved in numerous collaborative studies, particularly with Bo Angelin, and contributes to both experimental and clinical investigations in metabolic diseases. His research group focuses on liver metabolism, hormonal regulation, and cardiovascular risk factors.